A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

Inclusion Criteria: * Signed informed consent including data protection declaration prior to study participation * Subjects with confirmed cirrhosis (by biopsy, ultrasound, and/or laboratory examinations) * Ascites Grade II or Grade III at screening currently treated with at least one diuretic or the subject is considered intolerant to diuretics in the investigator's opinion Exclusion Criteria: * Age \<18 years of age * Any of the following laboratory findings at the time of screening * Serum creatinine level \>1.5mg/dL (\>132 µmol/L) * Serum Na+ \< 125 meq/L * Serum K+ ≥ 5.5 meq/L * Serum bilirubin ≥ 5 mg/dL (85.5 µmol/L) * INR \>3.0 * Women of childbearing potential with no effective contraceptive method (women of childbearing potential \[pre-menopausal, not surgically sterile for at least 3 months prior to the time of screening\] must have a confirmed negative serum β-hCG pregnancy test prior to enrolment and at Baseline Visit. They must use an effective contraceptive method throughout the study, and agree to repeat serum β-hCG pregnancy tests at designated visits) * Pregnancy or lactation * Systolic blood pressure \<90 mmHg or diastolic blood pressure \<60 mmHg * Sepsis and/or uncontrolled bacterial infection * Current or recent documented nephrotoxicity (within 4 weeks) * Hepatic Encephalopathy above grade 1 * History of variceal bleeding in the last 2 months * Suspicion of active alcohol consumption in the last 3 months * History of liver or kidney transpl…